

# Dose-dependent and strain-dependent anti-obesity effects of *Lactobacillus sakei* in a diet induced obese murine model

Yosep Ji<sup>1,\*</sup>, Young Mee Chung<sup>2,\*</sup>, Soyoung Park<sup>1</sup>, Dahye Jeong<sup>2</sup>, Bongjoon Kim<sup>2</sup> and Wilhelm Heinrich Holzapfel<sup>1</sup>

<sup>1</sup> Department of Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, South Korea

<sup>2</sup> Beneficial Microbes Center, CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Gyeonggi, South Korea

\* These authors contributed equally to this work.

## ABSTRACT

**Background:** Overweight and abdominal obesity, in addition to medical conditions such as high blood pressure, high blood sugar and triglyceride levels, are typical risk factors associated with metabolic syndrome. Yet, considering the complexity of factors and underlying mechanisms leading to these inflammatory conditions, a deeper understanding of this area is still lacking. Some probiotics have a reputation of a relatively-long history of safe use, and an increasing number of studies are confirming benefits including anti-obesity effects when administered in adequate amounts. Recent reports demonstrate that probiotic functions may widely differ with reference to either intra-species or inter-species related data. Such differences do not necessarily reflect or explain strain-specific functions of a probiotic, and thus require further assessment at the intra-species level. Various anti-obesity clinical trials with probiotics have shown discrepant results and require additional consolidated studies in order to clarify the correct dose of application for reliable and constant efficacy over a long period.

**Methods:** Three different strains of *Lactobacillus sakei* were administered in a high-fat diet induced obese murine model using three different doses,  $1 \times 10^{10}$ ,  $1 \times 10^9$  and  $1 \times 10^8$  CFUs, respectively, per day. Changes in body and organ weight were monitored, and serum chemistry analysis was performed for monitoring obesity associated biomarkers.

**Results:** Only one strain of *L. sakei* (CJLS03) induced a dose-dependent anti-obesity effect, while no correlation with either dose or body or adipose tissue weight loss could be detected for the other two *L. sakei* strains (L338 and L446). The body weight reduction primarily correlated with adipose tissue and obesity-associated serum biomarkers such as triglycerides and aspartate transaminase.

**Discussion:** This study shows intraspecies diversity of *L. sakei* and suggests that anti-obesity effects of probiotics may vary in a strain- and dose-specific manner.

Submitted 26 September 2018

Accepted 20 February 2019

Published 21 March 2019

Corresponding author

Wilhelm Heinrich Holzapfel,  
wilhelm@woodapple.net

Academic editor

Lesley Hoyles

Additional Information and  
Declarations can be found on  
page 13

DOI 10.7717/peerj.6651

© Copyright  
2019 Ji et al.

Distributed under  
Creative Commons CC-BY 4.0

OPEN ACCESS

**Subjects** Biotechnology, Microbiology

**Keywords** Probiotic, Dose dependency, *Lactobacillus sakei*, Obesity, Strain specificity, Fat mass

## INTRODUCTION

Overweight and obesity result from abnormal adipose deposition and function and are considered as major pathophysiological symptoms of metabolic syndrome (*Olufadi & Byrne, 2008*). Originating from insulin resistance, metabolic syndrome may be reflected by several clinical manifestations such as atherosclerosis, hyperglycemia, dyslipidemia, hypertension, reduced high density lipoprotein (HDL) cholesterol and type 2 diabetes mellitus (*Furukawa et al., 2017*). Based on typical pathological symptoms, broadly defined as excessive fat mass in the body (specifically the abdomen), the prevalence of obesity has rapidly increased during the last two decades (*Kobyliak et al., 2017*). Also referred to as “obesity pathogenesis,” obesity is considered as a disorder of the energy homeostasis system rather than the result of passive weight accumulation (*Schwartz et al., 2017*). In spite of the recent intensive research input, a deeper understanding of pathogenesis and the underlying mechanisms of obesity are still lacking, while, in fact, the causality of obesity has been explained from different viewpoints and disciplines of science such as genetics, endocrinology and psychology (*Schwartz et al., 2017*).

Following up on classical approaches, recent studies show that the microbiota can play a key role in host obesity and metabolic syndrome (*Gérard, 2016*). Thereby, new clinical diagnostic perspectives were opened on the influence of the gut microbiota on the status of metabolic disorders. This potential has been highlighted in a review by *Boulange et al. (2016)*, at the same time underlining the complex etiology of these disorders. The current understanding of the mechanisms linking the gut microbiota with metabolic syndrome still appears to be “vague” (*Chattopadhyay & Mathili, 2018*). Indeed, numerous studies have reported on qualitative and quantitative discrepancies in the microbiota of the gastrointestinal tract (GIT) when comparing healthy subjects with people suffering from metabolic diseases (*Turnbaugh et al., 2006, 2008; Ley et al., 2005; Cani & Delzenne, 2009; Armougom et al., 2009*).

The International Scientific Association for Probiotics and Prebiotics, after a grammatic correction, has condoned the FAO/WHO consensus definition of probiotics as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (*Hill et al., 2014*). There is general agreement that probiotics support the balance of the host gut microbiota, and scientific evidence is steadily accumulating regarding the positive impact of probiotics on human health such as improvement of immune disorders, inflammatory bowel disease, type 2 diabetes and atherosclerosis (*Amar et al., 2011; Kim et al., 2016; Ritze et al., 2014; Schroeder et al., 2018; Vemuri, Gundamaraju & Eri, 2017*). In spite of increasing evidences of beneficial effects, information is still sparse on the way in which gut microbiota communicates with distant sites in the host, and also on the mechanisms underlying their influence on host physiology with regard to (e.g.,) the respiratory system, the skin, brain, heart and host metabolism (*Reid et al., 2017*). The best recognized mechanisms among the studied probiotics appear to be related to colonization resistance, acid and short-chain fatty acid production, regulation of intestinal transit, normalization of perturbed microbiota, increasing turnover of enterocytes, and competitive exclusion of pathogens (*Hill et al., 2014*). Using a high-calorie induced

obesity BALB/c mouse model a single strain of *Lactobacillus casei* IMV B-7280, and a combination of *Bifidobacterium animalis* VKL, *B. animalis* VKB and *L. casei* IMV B-7280 were shown to be effective in reducing weight gain and cholesterol levels, in the restoration of liver morphology and in modulating the gut microbiome in a beneficial manner (Bubnov et al., 2017). However, key issues such as strain-specificity and characterization of dose-dependent effects still remain to be solved. For this purpose, the further development of both in vitro and in vivo models appears to be strongly justified. Evidence-based recommendations for probiotics presently suggest a dose of  $10^9$  CFU/day or higher (WGO, 2017). A former study involving volunteers demonstrated a dose of  $10^{11}$  CFU/day (of probiotic strains *B. animalis* subsp. *lactis* BB-12 and *L. paracasei* subsp. *paracasei* CRL-341) to be effective (Larsen et al., 2006). For the clinical success of anti-obesity treatment, selection of an optimal dose and an optimal administration time frame of probiotics are considered to be essential for inducing beneficial changes, both in gut microbiome diversity and in the metabolism of obese humans (Bubnov et al., 2017).

Various modes of probiotic action were elucidated by using in vitro studies (including development of dedicated in vitro models) while efficacy was investigated by both in vivo (preclinical) studies (Park et al., 2016; Wang et al., 2015) and clinical trials (Kadooka et al., 2010; Woodard et al., 2009). These therapeutic benefits were all related to anti-obesity effects of probiotics (Kadooka et al., 2010; Park et al., 2016; Wang et al., 2015; Woodard et al., 2009). Yet, the anti-obesity efficacy of probiotics has not been fully elucidated in spite of various clinical trials, and scientific evidence for a “minimal dose effect level” remains relatively sparse (Tanentsapf, Heitmann & Adegboye, 2011; Raoult, 2009; Mekkes et al., 2013). The concept of a minimal effective dose is complicated due to the large (and diverse) number of microbial and host-related factors (Salminen et al., 1998), and will also depend on the kind of key criteria and the “end-points” selected. The dose of intolerance is generally considered to be high; thus, allowing a relatively broad “therapeutic window” (Collins, Thornton & Sullivan, 1998), it may be difficult to find a suitably low effective dose above the minimal level. Yet, precisely defining an effective dose has remained an arbitrary issue, and thus the pragmatic suggestion by an FAO/WHO Working Group (FAO/WHO, 2002) that “the suggested serving size must deliver the effective dose of probiotics related to the health claim.” Convincingly delivering this kind of evidence has remained difficult until this day, in particular for commercial distribution of (food or pharmaceutical) strains claimed to be probiotics. In an early report Perdigón, Alvarez & De Ruiz Holgado (1991) suggested a dose related impact of *L. casei* on the secretory immune response and protective capacity in intestinal infections. A placebo-controlled study designed to evaluate the therapeutic value of four different non-antibiotic preparations (including *Saccharomyces boulardii*, and heat-killed microbial strains) indicated a non-significant dose dependency for either prophylaxis or treatment of traveller’s diarrhoea (Kollaritsch et al., 1989, 1993). Yet, substantial evidence supports the principle of dose-dependency of probiotics to modulate systemic and mucosal immune function, improve intestinal barrier function, alter gut microbiota, and exert metabolic effects on the host, also in a strain-dependent manner (Alemka et al., 2010; Madsen, 2012; Larsen et al., 2013).

Everard et al. (2011) reported a dose-dependent immunomodulation of human dendritic cells by the probiotic *L. rhamnosus* Lcr35, leading, at high doses, to the semi-maturation of the cells and to a strong pro-inflammatory effect. Against this background, the present study was designed with the challenge of involving a hitherto rarely reported species (*L. sakei*) and its potential for alleviation of obesity (in a diet-induced obese (DIO) mouse model). In addition, there was the prospect of gaining additional insights in intra-species (strain-specific) functional diversity by using established biomarkers.

In this study we administered three different 10-fold dose levels of three different *L. sakei* strains separately to a DIO C57BL/6 murine model and monitored body weight during the full experimental period. Organ weights and serum biomarkers were monitored to elucidate the dose-dependent anti-obesity effect of three different *L. sakei* strains.

## MATERIALS AND METHODS

### Animal studies

The animal study was approved by the Ethical Committee of KPC Ltd. in Korea (P150067), in full compliance with ethical standards as specified by Korean law. A total of 5 week-old, specific pathogen free male C57BL/6 mice were supplied from Orient Bio, Korea. Either a high-fat diet (HFD) (Research Diets D12492) (60% kcal fat), or low-fat diet (LFD) (Purina Laboratory Rodent Diet 38057) (12% kcal fat) (negative control) and autoclaved tap water were provided ad libitum, while the animals were housed at 23 °C, 55 ± 10% humidity, in a 12 h light/dark cycle. At the age of 5 weeks mice were fed with either a low-fat control diet containing 12% kcal of total energy from fat (12.41% kcal fat, 24.52% protein, 63.07% kcal carbohydrate (Purina Laboratory Rodent Diet 38057; Purina Korea Inc., Seoul, Korea)) or a HFD with 60% kcal fat ((90% of the fat from lard, 10% from soybean oil), 20% kcal protein, 20% kcal carbohydrate (D12492; Research Diets Inc., New Brunswick, NU, USA)) for 6 weeks. For this study, a HFD of 60% kcal fat was chosen, as this is one of the most commonly used diets to induce obesity and ectopic lipid storage in in vivo studies. Detailed analytical information on the diet composition is given in Table S1 (see also Table 1). The NIH guidelines were followed by providing sufficient cage surface area based on the weight of the mice. In total 120 mice were separated into 12 different groups (five animals per cage and two cages per group) with each group receiving a different treatment. Study design is given in Table 2 and information on the diets in Table 1.

The experiment comprised 1 week of adaptation followed by 6 weeks of obesity induction using a HFD while the LFD group was maintained on LFD feeding. A total number of 110 mice received the test substances, with exception of those with the upper and lower body weights after the 6-week period of obesity induction. All treatments were by oral gavage and were performed twice a day, at the same daytime (10.00 and 17.00), for 7 weeks. Each group was treated with either the microbial culture suspended in phosphate buffered saline (PBS), orlistat suspended in PBS, as chemical control, or only PBS as negative control. Orlistat was provided as Xenical (with 120 mg/g of orlistat as active pharmaceutical ingredient, and microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, povidone and talc as inactive ingredients). The contents of the

**Table 1** Diet composition of the low-fat (LFD) and high-fat (HFD) diets used in this study.

**A.**

Calories (%)	Ingredients					
	Protein (%)	Fat (%)	Fiber (%)	Minerals (%)	Vitamins (%)	
Fat	12.41%	Arginine (1.26)	Linoleic Acid (1.10)	Crude fiber	Ash (7.25)	Vitamins A, D3, E, K, Riboflavin, Niacin Others
Carbohydrate	63.07%	Glycine (0.87)	Linolenic Acid (0.12)		Calcium (1.20)	
Protein	24.52%	Isoleucine (0.82)	Arachidonic Acid (0.02)		Phosphorus (0.62)	
		Leucine (1.47)	Omega-3 Fatty Acids		Potassium (0.82)	
		Lysine (1.01)	(1.11)		Others	
		Phenylalanine (0.98)				
		Valine (0.91)				
		Others				
Total	100%	20	4.5	3.7		

**B.**

Calories (kcal%)	Ingredients (g)
Fat	60.00%
Carbohydrate	20.00%
Protein	20.00%
	Casein, 80 Mesh (200)
	L-Cystine (3)
	Maltodextrin 10 (125)
	Sucrose (68.8)
	Cellulose, BW 200 (50)
	Soybean Oil (25)
	Lard (245)
	Mineral Mix, S10026 (10)
	DiCalcium Phosphate (13)
	Calcium Carbonate (5.5)
	Potassium Citrate.1H <sub>2</sub> O (16.5)
	Vitamin Mix, V10001 (10)
	Choline Bitartrate (2)
	FD&Blue Dye #1 (0.05)
Total	100%
	773.85

**Note:**

(A) Low-fat diet (Purina Laboratory Rodent Diet 38057); (B) high-fat diet (Research Diets D12492).

Xenical capsules were added to PBS, as explained in [Table 1](#). As orlistat is insoluble in water, it was suspended by vortexing and sonication and then orally administered to the animals. For oral administration each microbial strain was washed twice with PBS and the supernatant discarded after centrifugation. The microbial pellet was resuspended in PBS to suit the dose for administration. On the last day of the experiment, the mice were sacrificed by dislocation of the cervical vertebra. The organs (liver, femoral muscle, brown adipose tissue, epididymal adipose tissue, subcutaneous adipose tissue and mesenteric adipose tissue) were collected, weighed, and stored at  $-80^{\circ}\text{C}$ . Each perfused liver was embedded in paraffin and sectioned (four  $\mu\text{m}$ ) on a microtome. Hematoxylin and eosin (H&E) staining was performed on each high dose *L. sakei* group and assessed by light microscopy (Olympus MVX10 microscope, equipped with a DC71 camera; Center Valley, PA, USA; Olympus, Tokyo, Japan).

Serum triglycerides (TG), glucose (GLU), total cholesterol (TC), HDL, low-density lipoprotein (LDL) and aspartate transaminase (AST; a marker of liver toxic injuries of

**Table 2** Study design and animal treatments based on a high-fat (HFD) and low-fat diet (LFD).

Group	Feed type	Treatment
LFD	LFD	300 $\mu$ L PBS (non-obese control)
HFD	HFD	300 $\mu$ L PBS (obese control)
Orlistat	HFD	40 mg/kg suspended in 300 $\mu$ L PBS
CJB38 L	HFD	$1 \times 10^8$ CFU/day of <i>L. sakei</i> L338 suspended in 300 $\mu$ L PBS
CJB38 M	HFD	$1 \times 10^9$ CFU/day of <i>L. sakei</i> L338 suspended in 300 $\mu$ L PBS
CJB38 H	HFD	$1 \times 10^{10}$ CFU/day of <i>L. sakei</i> L338 suspended in 300 $\mu$ L PBS
CJB46 L	HFD	$1 \times 10^8$ CFU/day of <i>L. sakei</i> L446 suspended in 300 $\mu$ L PBS
CJB46 M	HFD	$1 \times 10^9$ CFU/day of <i>L. sakei</i> L446 suspended in 300 $\mu$ L PBS
CJB46 H	HFD	$1 \times 10^{10}$ CFU/day of <i>L. sakei</i> L446 suspended in 300 $\mu$ L PBS
CJLS03 L	HFD	$1 \times 10^8$ CFU/day of <i>L. sakei</i> LS03 suspended in 300 $\mu$ L PBS
CJLS03 M	HFD	$1 \times 10^9$ CFU/day of <i>L. sakei</i> LS03 suspended in 300 $\mu$ L PBS
CJLS03 H	HFD	$1 \times 10^{10}$ CFU/day of <i>L. sakei</i> LS03 suspended in 300 $\mu$ L PBS

**Note:**

LFD, low-fat diet (negative control); HFD, high-fat diet; CJB38, CJB46 and CJLS03 denote the three *Lactobacillus sakei* strains; the three dose levels of each strain administered together with the HFD were  $1 \times 10^{10}$  CFU/ml (high-dose, H),  $1 \times 10^9$  (medium-dose, M) and  $1 \times 10^8$  CFU/mL (low-dose, L).

hepatocytes (Aulbach & Amuzie, 2017)), were measured using an automated biochemical analyzer BS-200 (Mindray, China) in Pohang Technopark, Pohang (South Korea).

## Microorganisms

*Lactobacillus sakei* strain CJLS03 was isolated from kimchi, while *L. sakei* strains CJB38 and CJB46 originated from human fecal samples. These strains were selected among nine different strains (comprising four *L. brevis*, three *L. sakei*, one *L. plantarum* and one *Bifidobacterium longum*) on the basis of the lowest weight gain in a preliminary study using a DIO mouse model (data shown in Fig. S1).


The three *L. sakei* strains were grown daily in MRS broth (Difco Laboratories INC., Franklin Lakes, NJ, USA) for feeding during the 7-week period of intervention. Strains were grown for 8 h to reach their late log phase and were collected by centrifugation (3,546g, 5 min, 5 °C) (Hanil Science Inc., Gangneung, South Korea) and washed two times with PBS. Each strain was prepared in an approximate number of  $1 \times 10^{10}$  CFU/ml using a mathematical equation derived from a pre-optimised standard curve (Fig. S2) using optical density by SPECTROstar Nano (BMG Labtech, Durham, NC, USA). A stock suspension of  $1 \times 10^{10}$  CFU/mL (high-dose, H) was prepared of each strain, then diluted 10-fold to  $1 \times 10^9$  (medium-dose, M) and  $1 \times 10^8$  CFU/mL (low-dose, L), respectively, and finally suspended in 300  $\mu$ L of PBS to be administered to each mouse by oral gavage.

Experimental determinants were statistically calculated using ANOVA and Dunnett's multiple comparison test to distinguish the level of significance based on probability of 0.05 (\*), 0.01 (\*\*) and 0.001 (\*\*\*)

## RESULTS

High-fat diet feeding resulted in a strong increase in body mass as compared to those animals receiving LFD administration (Fig. 1A) over the 48-day feeding period. Moreover,






**Figure 1** (A) Body weight after 48 days, and (B–D) increase over the 48-day period; (E) body weight gain after 48 days, and (F) daily feed consumption of each group. LFD, low-fat diet; HFD, high-fat diet; CJB38, CJB46 and CJLS03 denote the three *L. sakei* strains; the three dose levels of each strain administered together with the HFD were  $1 \times 10^{10}$  CFU/mL (high-dose, H),  $1 \times 10^9$  (medium-dose, M) and  $1 \times 10^8$  CFU/mL (low-dose, L). The values for each index are expressed as the mean  $\pm$  SD ( $n = 10$ ). Asterisks denote the level of significance compared to HFD as \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

Full-size [DOI: 10.7717/peerj.6651/fig-1](https://doi.org/10.7717/peerj.6651/fig-1)

elevated levels of serum biomarkers such as TG, TC, GLU, LDL and AST were detected in the HFD group (Fig. 2), concomitantly with quantitative increases in epididymal, mesenteric and subcutaneous adipose tissues (Fig. 3). Orlistat therapy did not cause any mentionable side-effects in the treated animals. No animals in any of the groups died during the study period.

Three different doses ( $10^8$ – $10^{10}$ ) of the three *L. sakei* strains (CJB38, CJB46 and CJLS03) were orally administered to high fat DIO C57BL/6 mice for 7 weeks, and body weight and food consumption were measured daily. During the test period, three strains were found to exhibit reduced weight gain compared to the HFD group (Figs. 1B–1D),




**Figure 2** Serum biomarkers of each experimental group showing (A) triglycerides, (B) glucose, (C) total cholesterol, (D) high density lipoprotein (HDL), (E) low density lipoprotein (LDL) and (F) aspartate transaminase (AST). LFD, low-fat diet; HFD, high-fat diet; CJB38, CJB46 and CJLS03 denote the three *L. sakei* strains; the three dose levels of each strain administered together with the HFD were  $1 \times 10^{10}$  CFU/mL (high-dose, H),  $1 \times 10^9$  (medium-dose, M) and  $1 \times 10^8$  CFU/mL (low-dose, L). The values for each index are expressed as the mean  $\pm$  SD ( $n = 10$ ). Asterisks denote the level of significance compared to HFD as \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

Full-size [DOI: 10.7717/peerj.6651/fig-2](https://doi.org/10.7717/peerj.6651/fig-2)

with strain CJLS03 showing, dose-dependently, the strongest effect of the three strains. LFD, Orlistat, the full CJB46 group, and medium and high dose of the CJLS03 groups showed significantly lower weight increase compared to the HFD group (Fig. 1E; Fig. S3). The weight loss of CJB38 or CJB46 was not dependent of the dose while only strain CJLS03 showed a dose-dependent weight reduction effect, and with the highest efficacy of all groups for CJLS03 H (Fig. 1E). The onset time of weight loss showed significance compared to the HFD at days 4, 21, 21 and 7 for the Orlistat, CJB38, CJB46 and





**Figure 3** Organ weights of each experimental group showing (A) epididymal adipose tissue, (B) mesenteric adipose tissue, (C) subcutaneous adipose tissue, (D) brown adipose tissue, (E) liver and (F) femoral muscle. LFD, low-fat diet; HFD, high-fat diet; CJB38, CJB46 and CJLS03 denote the three *L. sakei* strains; the three dose levels of each strain administered together with the HFD were  $1 \times 10^{10}$  CFU/mL (high-dose, H),  $1 \times 10^9$  (medium-dose, M) and  $1 \times 10^8$  CFU/mL (low-dose, L). The values for each index are expressed as the mean  $\pm$  SD ( $n = 10$ ). Asterisks denote the level of significance compared to HFD as \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

Full-size DOI: 10.7717/peerj.6651/fig-3

CJLS03 groups, respectively (Table S2). The daily dietary intake was significantly higher in the LFD, Orlistat and CJLS03 M groups compared to the HFD group (Fig. 1F).

Serum biochemical analysis showed an overall increase in the lipid profile (TC, TG, HDL, LDL), liver (AST) and the GLU level of the HFD group compared to the LFD group, demonstrating that a HFD intake may impact various biomarkers associated with pathophysiological symptoms of obesity (Fig. 2). Compared to the HFD group, the serum TG level decreased in all test groups (Fig. 2A) while the LDL level was significantly reduced

in all test groups except CJB46 H (Fig. 2E). Significant reduction of TC was only detected in LFD, Orlistat and in the groups treated with higher doses (M and H) of *L. sakei* CJB38 H, CJB46 M, CJB46 H, CJLS03 M and CJLS03 H (Fig. 2C). In particular, the CJLS03 group, shown to be superior regarding weight gain inhibition, appears to be effective in a dose-dependent manner (Figs. 2A–2C). HDL levels were not significantly different from the HFD group in all the test groups, however, all *L. sakei* treated groups except CJB46 L, CJLS03 M and CJLS03 H showed significant increase when the ratio of HDL to TC level was calculated; this is reflected in Fig. 2D. Serum AST values (indicating liver function) were found to be approximately 1.7 times higher for the HFD compared to the LFD group (Fig. 2F), while the Orlistat group showed no significant change in AST level compared to the HFD group. All nine groups receiving the *L. sakei* strains showed a trend toward reduced AST levels but with only the high dose of CJLS03 (CJLS03 H) differing significantly when compared to the HFD group (Fig. 2F). CJLS03 showed the highest overall effectivity and a dose-dependent anti-obesity function; at the same time, it induced a dose-dependent improvement of serum obesity-associated biomarkers and liver function. Liver H&E staining optically demonstrated normal histology in LFD mice with minor lipid accumulation. Comparing the visual differences, the HFD-fed mice showed extensive fat accumulation and moderate vacuolations around the portal triad. In the groups treated with the higher dose of *L. sakei* CJB38 H, CJB46 H and CJLS03 H inhibition of lipid accumulation was visually evident and was comparable to that of the LFD group (Fig. S4).

Compared to HFD the LFD group showed significantly lower weights of epididymal, mesenteric, subcutaneous and brown adipose tissues while insignificant organ weight differences were measured in liver and femoral muscles (Fig. 3). Every dose of all three strains of *L. sakei* and the orlistat treatment resulted in significantly lower subcutaneous adipose tissue weight while only CJLS03 H showed significant reduction of visceral adipose tissue including epididymal and mesenteric adipose tissue, when compared to the HFD group (Figs. 3A–3C). CJLS03 M treatment significantly reduced epididymal adipose tissue weight when compared to the HFD group (Fig. 3A). These results suggest that the three different *L. sakei* strains inhibited the accumulation of subcutaneous adipose tissue but that the CJLS03 group responded by dose-dependent reduction of visceral adipose tissues including the epididymal and mesenteric adipose tissues (Figs. 3A and 3B). Orlistat and *L. sakei* treatment did not result in significant weight differences regarding brown adipose tissue, liver and femoral muscle (Figs. 3D–3F).

## DISCUSSION

The impact of a HFD on various biomarkers associated with pathophysiological symptoms of obesity is well established and supported in current literature (Chandler *et al.*, 2017; Lee, 2013; Ludwig *et al.*, 2018; Siri-Tarino *et al.*, 2010). The body mass increase resulting from HFD feeding (as compared to a LFD) in this study (Fig. 1) was also accompanied by significant increases in serum biomarkers such as TG, TC, GLU, LDL and AST (Fig. 2) and also increases in epididymal, mesenteric and subcutaneous adipose tissues (Fig. 3). Definition of an ideal HFD and its exact composition is generally considered

difficult (Buettner, Schölmerich & Bollheimer, 2007). However, the standardization of the specific laboratory and feeding conditions for the purpose of metabolic studies is essential. In our studies, we have used exactly defined and commercially available HFD and LFD. The selected murine model (male C57BL/6 mice) is widely preferred as in vivo model for obesity and metabolic studies (Khan et al., 2014) and related investigations (Neuhofner et al., 2014).

The anti-obesity influence of administered probiotics is a heavily debated issue, yet, an indisputable fact is that the host gut microbiota is exercising a leverage over energy efficiency and adipose tissue accumulation (Kobyliak et al., 2017; Greiner & Bäckhed, 2011; Delzenne et al., 2011). At the same time, probiotics have been reported to impact the host microbiota in a positive way (Hemarajata & Versalovic, 2013) and to beneficially influence gut homeostasis and reduce the symptoms of gastrointestinal diseases (Bron et al., 2017). The beneficial effect of probiotics on the levels of alanine aminotransferase, AST, TC, HDL, tumor necrosis factor- $\alpha$  and also on insulin resistance (assessed in a homeostasis model (HOMA-IR)) have been reported earlier (Ma et al., 2013). In a study using C57BL/6J mice *L. rhamnosus* GG (LGG) showed a protective effect against nonalcoholic fatty liver disease (NAFLD) induced by a high-fructose diet (Ritze et al., 2014). This potential is supported by meta-analysis of data from randomized controlled trials in patients with NAFLD, showing probiotic therapy to result in a significant decrease of NAFLD (Ma et al., 2013; Al-muzafar & Amin, 2017). Moreover, probiotic therapy has been shown to be typically associated with a reduction in liver aminotransferase levels (Aller et al., 2011; Buss et al., 2014; Shavakhi et al., 2013). The significant reduction of liver AST levels by *L. sakei* CJLS03 H in our study suggests its possible therapeutic potential for alleviation of NAFLD. The potential advantages of probiotics as complementary treatment for metabolic disorders and as therapy for NAFLD are increasingly recognized (Le Barz et al., 2015; Ma, Zhou & Li, 2017). Moreover, the modulatory effect of probiotics on the gut microbiota suggests their potential as a “promising and innovative add-on therapeutic tool” for the treatment of NAFLD (Paolella et al., 2014). In our study, inhibition of hepatic lipid accumulation in HFD animals was revealed by Liver H&E staining and was particularly obvious for the groups treated with orlistat and CJLS03 H which also compared well with the normal histological features of the LFD group (Fig. S4).

The function of orlistat in assisting weight loss is well established and has been supported by Cochrane meta-analysis of various randomized controlled trials (Drew, Diuxon & Dixon, 2007). Obesity control may be by several mechanisms, one of which being that orlistat prevents fat hydrolysis by acting as a gastric and pancreatic lipase inhibitor (Heck, Yanovski & Calis, 2012; Yanovski & Yanovski, 2014). It has been successfully used as anti-obesity control in animal experiments involving high fat DIO rats (Karimi et al., 2015) and DIO C57BL/6 mice (Chung et al., 2016). The latter studies also included clinical trials, and the authors (Chung et al., 2016) claimed orlistat to be the most popular anti-obesity pharmaceutical drug, both in animal (DIO C57BL/6 mice) experiments and clinical trials. The DIO C57BL/6 mouse is now widely accepted as an in vivo model of choice. It has been reported to closely reflect human metabolic disorders such as obesity, hyperinsulinemia, hyperglycemia and hypertension (Collins et al., 2004).

In particular, the metabolic abnormalities of DIO C57BL/6 after HFD feeding are considered reported to closely resemble those of human obesity development patterns ([Speakman et al., 2007](#)), and also regarding properties such as adipocyte hyperplasia, fat deposition in the mesentery and increased fat mass ([Inui, 2003](#)).

Probiotic administration increasingly enjoys consideration as a promising approach for beneficially modulating the host microbiota ([Jia et al., 2008](#); [Steer et al., 2000](#)). Numerous reports confirmed the beneficial effects of specific probiotic strains against diarrhoea and inflammatory bowel diseases ([Ahmadi, Alizadeh-Navaei & Rezai, 2015](#); [Gionchetti et al., 2000](#); [Ouwehand, Salminen & Isolauri, 2002](#)). Recently, anti-obesity effects of probiotics were also reported and confirmed in clinical trials ([Kadooka et al., 2010](#); [Woodard et al., 2009](#); [Minami et al., 2015, 2018](#); [Borgeraas et al., 2017](#)) and animal models ([Kim et al., 2016](#); [Alard et al., 2016](#); [Wang et al., 2015](#); [Ji et al., 2012](#)). [Kadooka et al. \(2010\)](#) investigated the anti-obesity effect of the probiotic *L. gasseri* SBT2055 by conducting a double-blind, randomized, placebo-controlled intervention trial with 87 overweight and obese subjects for 12 weeks. The data confirmed that the abdominal visceral and subcutaneous fat area, weight, BMI, as well as waist and hip measures were significantly reduced in the group consuming the probiotic. In another study ([Woodard et al., 2009](#)) 44 morbid obese patients were operated for weight loss by surgery (gastric bypass surgery) and were randomly divided in a probiotic administered group and a control group. A significantly higher weight loss was recorded in the group receiving the probiotic (described as “Puritan’s Pride<sup>®</sup>,” containing a mixture of 2.4 billion live cells of *Lactobacillus* spp.). [Park et al. \(2013\)](#) reported a significant weight reduction of a C57BL/6 mice model after *L. curvatus* HY7601 and *L. plantarum* KY1032 consumption, however, faecal microbiota modulation of major groups such as *Firmicutes* and *Bacteroidetes* was not monitored.

One of the major hurdles for an accurate clinical trial is to understand the effective dose of a probiotic at a strain-specific level. Selecting the correct dose of a probiotic for a specific purpose such as the alleviation of diarrhoea was suggested in various studies; yet, there is a general lack of scientific proof of a concept to define the functional dose of a probiotic ([Kollaritsch et al., 1989, 1993](#); [Islam, 2016](#)). [Chen et al. \(2015\)](#) used a range of five different 10-fold doses of *L. acidophilus* in a colitis-induced animal model and reported  $10^6$  CFU/10 g of the animal weight as the most effective application level for modulating the bacterial profile in the distal colon. In our study we have monitored dose-related effects of three different strains of *L. sakei* and found only one strain, CJLS03, to show a dose-dependent anti-obesity effect while the anti-obesity impact of the other two strains was lower and dose-independent ([Fig. S3](#)). At dose levels from  $1 \times 10^8$  to  $1 \times 10^{10}$  CFU/mL administration of strain CJLS03 resulted in a dose-related (progressive) reduction in the levels of TC, TG, AST, mesenteric adipose tissue and epididymal adipose tissue ([Fig. S3](#)). Adipose tissues were reduced relative to weight gain, and TG and TC showed the most significant reduction in the *L. sakei* treated groups compared to the HFD control group. Another *L. sakei* strain (OK67) isolated from kimchi was reported to ameliorate HFD-induced blood GLU intolerance and obesity in mice; mechanisms for this effect have been suggested to be by inhibition of gut microbial

lipopolysaccharide production and the inducing of colon tight junction protein expression (*Lim et al., 2016*).

Our study has confirmed the relevance of a strain-specific approach when selecting functional strains suitable for (costly and time-consuming) clinical studies. The importance of this issue has been emphasized in recent papers with regard to pre-clinical physiological studies on putative probiotic strains of lactic acid bacteria and *Bifidobacterium*. These studies involved features such as adhesion potential, antibiotic resistance and survival under simulated conditions of the upper GIT, in addition to the modulation of the gut microbiome (*Bubnov et al., 2018*).

## CONCLUSIONS

This in vivo investigation showed that beneficial effects of putative probiotics are both strain-specific and dose-related. For only one (CJLS03) out of three *L. sakei* strains an anti-obesity effect could be detected, which, at the same time, was found to be dose-dependent. The highest of three doses ( $1 \times 10^{10}$  CFU/day) of CJLS03 gave the most favorable (significant) biomarker-related effects with regard to cholesterol and triglyceride reduction, when compared to the HFD control.

## ADDITIONAL INFORMATION AND DECLARATIONS

### Funding

This work was supported by the CJ CheilJedang Corporation, Seoul, South Korea, and the Bio and Medical Technology Development Program of the National Research Foundation (NRF) No. 2016M2A9A5923160 and 2018M3A9F3021964 (Ministry of Science, ICT & Future Planning). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Grant Disclosures

The following grant information was disclosed by the authors:

Bio and Medical Technology Development Program of the National Research Foundation (NRF): 2016M2A9A5923160 and 2018M3A9F3021964.

### Competing Interests

Yosep Ji, Soyoung Park and Wilhelm H Holzapfel have received research grants, via Handong Global University, from CJ CheilJedang Corporation, South Korea. Co-authors Young Mee Chung, Dahye Jeong and Bongjoon Kim are employed by CJ CheilJedang Corp., Blossom Park, Republic of Korea.

### Author Contributions

- Yosep Ji conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

- Young Mee Chung performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Soyoung Park performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Dahye Jeong conceived and designed the experiments, contributed reagents/materials/analysis tools.
- Bongjoon Kim conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper.
- Wilhelm Heinrich Holzapfel conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

### Animal Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The animal study was approved by the Ethical Committee of KPC Ltd. in Korea (P150067) in full compliance with ethical standards as specified by Korean law. KPC Ltd. is a commercial research institution dealing with contracted animals studies, and fully complies complying with Government standards for conducting animal studies. These include the involvement of a medical doctor and/or a veterinarian.

### Data Availability

The following information was supplied regarding data availability:

The raw data are available in the [Supplemental Files](#).

### Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.6651#supplemental-information>.

## REFERENCES

- Ahmadi E, Alizadeh-Navaei R, Rezai MS. 2015.** Efficacy of probiotic use in acute rotavirus diarrhea in children: a systematic review and meta-analysis. *Caspian Journal of Internal Medicine* **6(4)**:187–195.
- Alard J, Lehrter V, Rhimi M, Mangin I, Peucelle V, Abraham AL, Mariadassou M, Maguin E, Waligora-Dupriet AJ, Pot B, Wolowczuk I, Granette C. 2016.** Beneficial metabolic effects of selected probiotics on diet-induced obesity and insulin resistance in mice are associated with improvement of dysbiotic gut microbiota. *Environmental Microbiology* **18(5)**:1484–1497 DOI [10.1111/1462-2920.13181](https://doi.org/10.1111/1462-2920.13181).
- Alemka A, Clyne M, Shanahan F, Tompkins T, Corcionivoschi N, Bourke B. 2010.** Probiotic colonization of the adherent mucus layer of HT29MTXE12 cells attenuates *Campylobacter jejuni* virulence properties. *Infection and Immunity* **78(6)**:2812–2822 DOI [10.1128/IAI.01249-09](https://doi.org/10.1128/IAI.01249-09).
- Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. 2011.** Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver



disease patients: a double blind randomized clinical trial. *European Review for Medical and Pharmacological Sciences* 15:1090–1095.

- Al-muzafar HM, Amin KA. 2017.** Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. *BMC Complementary and Alternative Medicine* 17(1):43 DOI [10.1186/s12906-016-1540-z](https://doi.org/10.1186/s12906-016-1540-z).
- Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti P, Burcelin R. 2011.** Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. *EMBO Molecular Medicine* 3(9):559–572 DOI [10.1002/emmm.201100159](https://doi.org/10.1002/emmm.201100159).
- Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. 2009.** Monitoring bacterial community of human gut microbiota reveals an increase in *Lactobacillus* in obese patients and Methanogens in anorexic patients. *PLOS ONE* 4(9):e7125 DOI [10.1371/journal.pone.0007125](https://doi.org/10.1371/journal.pone.0007125).
- Aulbach AD, Amuzie CJ. 2017.** Biomarkers in nonclinical drug development. Chapter 17. In: Faqi AS, ed. *A Comprehensive Guide to Toxicology in Nonclinical Drug Development*. Second Edition. London: Academic Press (Elsevier), 447–471.
- Borgeraas H, Johnson LK, Skattebu J, Hertel JK, Hjelmæsæth J. 2017.** Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. *Obesity Reviews* 19(2):219–232 DOI [10.1111/obr.12626](https://doi.org/10.1111/obr.12626).
- Boulange CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E. 2016.** Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Medicine* 8(1):42 DOI [10.1186/s13073-016-0303-2](https://doi.org/10.1186/s13073-016-0303-2).
- Bron PA, Kleerebezem M, Brummer R-J, Cani PD, Mercenier A, MacDonald TT, Garcia-Ródenas CL, Wells JM. 2017.** Can probiotics modulate human disease by impacting intestinal barrier function? *British Journal of Nutrition* 117(1):93–107 DOI [10.1017/S0007114516004037](https://doi.org/10.1017/S0007114516004037).
- Bubnov RV, Babenko LV, Lazarenko LM, Mokrozub VV, Demchenko OA, Nechypurenko OV, Spivak MY. 2017.** Comparative study of probiotic effects of *Lactobacillus* and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice. *EPMA Journal* 8(4):357–376 DOI [10.1007/s13167-017-0117-3](https://doi.org/10.1007/s13167-017-0117-3).
- Bubnov RV, Babenko LV, Lazarenko LM, Mokrozub VV, Spivak MY. 2018.** Specific properties of probiotic strains: relevance and benefits for the host. *EPMA Journal* 9(2):205–223 DOI [10.1007/s13167-018-0132-z](https://doi.org/10.1007/s13167-018-0132-z).
- Buettner R, Schölmerich J, Bollheimer LC. 2007.** High-fat diets: modeling the metabolic disorders of human obesity in rodents. *Obesity* 15(4):798–808 DOI [10.1038/oby.2007.608](https://doi.org/10.1038/oby.2007.608).
- Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. 2014.** Probitoics and synbiotics may improve aminotransferases levels in non-alcoholic fatty liver disease patients. *Annals of Hepatology* 13(5):482–488.
- Cani PD, Delzenne NM. 2009.** Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. *Current Opinion in Pharmacology* 9(6):737–743 DOI [10.1016/j.coph.2009.06.016](https://doi.org/10.1016/j.coph.2009.06.016).
- Chandler M, Cunningham S, Lund EM, Khanna C, Naramore R, Patel A, Day MJ. 2017.** Obesity and associated comorbidities in people and companion animals: a one health perspective. *Journal of Comparative Pathology* 156(4):296–309 DOI [10.1016/j.jcpa.2017.03.006](https://doi.org/10.1016/j.jcpa.2017.03.006).

- Chattopadhyay A, Mathili S. 2018.** The journey of gut microbiome—an introduction and its influence on metabolic disorders. *Frontiers in Biology* **13**(5):327–341 DOI [10.1007/s11515-018-1490-6](https://doi.org/10.1007/s11515-018-1490-6).
- Chen L, Zou Y, Peng J, Lu F, Yin Y, Li F, Yang J. 2015.** *Lactobacillus acidophilus* suppresses colitis-associated activation of the IL-23/Th17 axis. *Journal of Immunology Research* **2015**:1–10 DOI [10.1155/2015/909514](https://doi.org/10.1155/2015/909514).
- Chung H-J, Yu JG, Lee I-A, Liu M-J, Shen Y-F, Sharma SP, Jamal MAHM, Yoo J-H, Kim H-J, Hong S-T. 2016.** Intestinal removal of free fatty acids from hosts by *Lactobacillus* for the treatment of obesity. *FEBS Open Bio* **6**(1):64–76 DOI [10.1002/2211-5463.12024](https://doi.org/10.1002/2211-5463.12024).
- Collins S, Martin TL, Surwit RS, Robidoux J. 2004.** Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. *Physiology & Behavior* **81**(2):243–248 DOI [10.1016/j.physbeh.2004.02.006](https://doi.org/10.1016/j.physbeh.2004.02.006).
- Collins JK, Thornton G, Sullivan GO. 1998.** Selection of probiotic strains for human applications. *International Dairy Journal* **8**(5–6):487–490 DOI [10.1016/S0958-6946\(98\)00073-9](https://doi.org/10.1016/S0958-6946(98)00073-9).
- Delzenne NM, Neyrinck AM, Bäckhed F, Cani PD. 2011.** Targeting gut microbiota in obesity: effects of prebiotics and probiotics. *Nature Reviews Endocrinology* **7**(11):639–646 DOI [10.1038/nrendo.2011.126](https://doi.org/10.1038/nrendo.2011.126).
- Drew BS, Diuxon AF, Dixon JB. 2007.** Obesity management: update on orlistat. *Vascular Health Risk Management* **3**(6):817–821.
- Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, De Vos WM, Delzenne NM, Schrenzel J, Cani PD. 2011.** Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. *Diabetes* **60**(11):2775–2786 DOI [10.2337/db11-0227](https://doi.org/10.2337/db11-0227).
- Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. 2017.** Increased oxidative stress in obesity and its impact on metabolic syndrome. *Journal of Clinical Investigation* **114**(12):1752–1761 DOI [10.1172/JCI200421625](https://doi.org/10.1172/JCI200421625).
- Gérard P. 2016.** Gut microbiota and obesity. *Cellular and Molecular Life Sciences* **73**(1):147–162 DOI [10.1007/s00018-015-2061-5](https://doi.org/10.1007/s00018-015-2061-5).
- Gionchetti P, Rizzello F, Venturi A, Campieri M. 2000.** Probiotics in infective diarrhoea and inflammatory bowel diseases. *Journal of Gastroenterology and Hepatology* **15**(5):489–493 DOI [10.1046/j.1440-1746.2000.02162.x](https://doi.org/10.1046/j.1440-1746.2000.02162.x).
- Greiner T, Bäckhed F. 2011.** Effects of the gut microbiota on obesity and glucose homeostasis. *Trends in Endocrinology and Metabolism* **22**(4):117–123 DOI [10.1016/j.tem.2011.01.002](https://doi.org/10.1016/j.tem.2011.01.002).
- Heck AM, Yanovski JA, Calis KA. 2012.** Orlistat, a new lipase inhibitor for the management of obesity. *Pharmacotherapy* **20**(3):270–279 DOI [10.1592/phco.20.4.270.34882](https://doi.org/10.1592/phco.20.4.270.34882).
- Hemarajata P, Versalovic J. 2013.** Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. *Therapeutic Advances in Gastroenterology* **6**(1):39–51 DOI [10.1177/1756283X12459294](https://doi.org/10.1177/1756283X12459294).
- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sander ME. 2014.** The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *National Reviews on Gastroenterology & Hepatology* **11**(8):506–514 DOI [10.1038/nrgastro.2014.66](https://doi.org/10.1038/nrgastro.2014.66).
- Inui A. 2003.** Obesity—a chronic health problem in cloned mice? *Trends in Pharmacological Sciences* **24**(2):77–80 DOI [10.1016/S0165-6147\(02\)00051-2](https://doi.org/10.1016/S0165-6147(02)00051-2).

- Islam SU. 2016. Clinical uses of probiotics. *Medicine* 95(5):e2658  
DOI 10.1097/MD.0000000000002658.
- Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, Yang JS, Park SY, Yoon HS, Cho GS, Franz CM, Bomba A, Shin HK, Holzapfel WH. 2012. Modulation of the murine microbiome with a concomitant anti-obesity effect by *Lactobacillus rhamnosus* GG and *Lactobacillus sakei* NR28. *Beneficial Microbes* 3(1):13–22 DOI 10.3920/BM2011.0046.
- Jia W, Li H, Zhao L, Nicholson JK. 2008. Gut microbiota: a potential new territory for drug targeting. *Nature Reviews Drug Discovery* 7(2):123–129 DOI 10.1038/nrd2505.
- Kadooka YM, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. 2010. Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *European Journal of Clinical Nutrition* 64(6):636–643 DOI 10.1038/ejcn.2010.19.
- Karimi G, Sabran MR, Jamaluddin R, Parvaneh K, Mohtarrudin N, Ahmad Z, Khazaai H, Khodavandi A. 2015. The anti-obesity effects of *Lactobacillus casei* strain Shirota versus Orlistat on high fat diet-induced obese rats. *Food & Nutrition Research* 59(1):29273  
DOI 10.3402/fnr.v59.29273.
- Khan M, Patrick AL, Fox-Robichaud AE. 2014. The Canadian Critical Care Translational Biology Group. 2014. Development of a murine model of early sepsis in diet-induced obesity. *BioMed Research International* 2014:1–11 DOI 10.1155/2014/719853.
- Kim B, Park K-Y, Ji Y, Park S, Holzapfel W, Hyun C-K. 2016. Protective effects of *Lactobacillus rhamnosus* GG against dyslipidemia in high-fat diet-induced obese mice. *Biochemical and Biophysical Research Communications* 473(2):530–536  
DOI 10.1016/j.bbrc.2016.03.107.
- Kobyliak N, Falalyeyeva T, Beregova T, Spivak M. 2017. Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition. *Endokrynologia Polska* 68(6):659–667 DOI 10.5603/EP.a2017.0055.
- Kollaritsch HH, Holst H, Grobara P, Wiedermann G. 1993. Prevention of traveler's diarrhea with *Saccharomyces boulardii*. Results of a placebo controlled double-blind study. *Fortschritte der Medizin* 111(9):152–156.
- Kollaritsch HH, Kremsner P, Wiedermann G, Scheiner O. 1989. Prevention of traveller's diarrhea: comparison of different non-antibiotic preparation. *Travel Medicine International* 6:9–17.
- Larsen CN, Nielsen S, Kaestel P, Brockmann E, Bennedsen M, Christensen HR, Eskesen DC, Jacobsen BL, Michaelsen KF. 2006. Dose–response study of probiotic bacteria *Bifidobacterium animalis* subsp. *lactis* BB-12 and *Lactobacillus paracasei* subsp. *paracasei* CRL-341 in healthy young adults. *European Journal of Clinical Nutrition* 60(11):1284–1293  
DOI 10.1038/sj.ejcn.1602450.
- Larsen N, Vogensen FK, Gobel RJ, Michaelsen KF, Forssten SD, Lahtinen SJ, Jakobsen M. 2013. Effect of *Lactobacillus salivarius* Ls-33 on fecal microbiota in obese adolescents. *Clinical Nutrition* 32(6):935–940 DOI 10.1016/j.clnu.2013.02.007.
- Le Barz M, Anhe FF, Varin TV, Desjardins Y, Levy E, Roy D, Urdaci MC, Marette A. 2015. Probiotics as complementary treatment for metabolic disorders. *Diabetes & Metabolism Journal* 39(4):291–303 DOI 10.4093/dmj.2015.39.4.291.
- Lee CY. 2013. The effect of high-fat diet-induced pathophysiological changes in the gut on obesity: what should be the ideal treatment? *Clinical and Translational Gastroenterology* 4(7):e39  
DOI 10.1038/ctg.2013.11.

- Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. 2005. Obesity alters gut microbial ecology. *Proceedings of the National Academy of Science of the United States of America* 102(31):11070–11075.
- Lim SM, Jeong JJ, Woo KH, Han MJ, Kim DH. 2016. *Lactobacillus sakei* OK67 ameliorates high-fat diet-induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression. *Nutrition Research* 36(4):337–348 DOI 10.1016/j.nutres.2015.12.001.
- Ludwig DS, Willett WC, Volek JS, Neuhouser ML. 2018. Dietary fact: from foe to friend? *Science* 362(6416):764–770 DOI 10.1126/science.aau2096.
- Ma Y-Y, Li L, Yu C-H, Shen Z, Chen L-H, Li Y-M. 2013. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. *World Journal of Gastroenterology* 19(40):6911–6918 DOI 10.3748/wjg.v19.i40.6911.
- Ma J, Zhou Q, Li H. 2017. Gut Microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy. *Nutrients* 9(10):1124 DOI 10.3390/nu9101124.
- Madsen KL. 2012. Enhancement of epithelial barrier function by probiotics. *Journal of Epithelial Biology and Pharmacology* 5(1):55–59 DOI 10.2174/1875044301205010055.
- Mekkes MC, Weenen TC, Brummer RJ, Claassen E. 2013. The development of probiotic treatment in obesity: a review. *Beneficial Microbes* 5(1):19–28 DOI 10.3920/BM2012.0069.
- Minami J, Iwabuchi N, Tanaka M, Yamauchi K, Xiao J, Abe F, Sakane N. 2018. Effects of *Bifidobacterium breve* B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial. *Bioscience of Microbiota, Food and Health* 37(3):67–75 DOI 10.12938/bmfh.18-001.
- Minami J, Kondo S, Yanagisawa N, Odamak T, Xiao J, Abe F, Nakajima S, Hamamoto Y, Saitoh S, Shimoda T. 2015. Oral administration of *Bifidobacterium breve* B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial. *Journal of Nutritional Science* 4:1–7 DOI 10.1017/jns.2015.5.
- Neuhof A, Wernly B, Leitner L, Sarai A, Sommer NG, Staffler G, Zeyda M, Stulnig TM. 2014. An accelerated mouse model for atherosclerosis and adipose tissue inflammation. *Cardiovascular Diabetology* 13(1):23 DOI 10.1186/1475-2840-13-23.
- Olufadi R, Byrne CD. 2008. Clinical and laboratory diagnosis of the metabolic syndrome. *Journal of Clinical Pathology* 61(6):697–706 DOI 10.1136/jcp.2007.048363.
- Ouwehand AC, Salminen S, Isolauri E. 2002. Probiotics: an overview of beneficial effects. *Lactic Acid Bacteria: Genetics, Metabolism and Applications* 82:279–289 DOI 10.1007/978-94-017-2029-8\_18.
- Paoella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. 2014. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. *World Journal of Gastroenterology* 20(42):15518–15531 DOI 10.3748/wjg.v20.i42.15518.
- Park DY, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R, Sung MK, McGregor RA, Choi MS. 2013. Supplementation of *Lactobacillus curvatus* HY7601 and *Lactobacillus plantarum* KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. *PLOS ONE* 8(3):e59470 DOI 10.1371/journal.pone.0059470.
- Park S, Ji Y, Park H, Lee K, Park H, Beck BR, Shin H, Holzapfel WH. 2016. Evaluation of functional properties of lactobacilli isolated from Korean white kimchi. *Food Control* 69:5–12 DOI 10.1016/j.foodcont.2016.04.037.
- Perdigón G, Alvarez S, De Ruiz Holgado AP. 1991. Immunoadjuvant activity of oral *Lactobacillus casei*: influence of dose on the secretory immune response and protective capacity in intestinal infections. *Journal of Dairy Research* 58(4):485–496 DOI 10.1017/s0022029900030090.

- Raoult D. 2009.** Probiotics and obesity: a link? *Nature Reviews Microbiology* 7(9):616  
DOI 10.1038/nrmicro2209.
- Reid G, Abrahamsson T, Bailey M, Bindels LB, Bubnov R, Ganguli K, Martoni C, O'Neill C, Savignac HM, Stanton C, Ship N, Surette M, Tuohy K, Van Hemert S. 2017.** How do probiotics and prebiotics function at distant sites? *Beneficial Microbes* 8(4):521–533  
DOI 10.3920/BM2016.0222.
- Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, Bischoff SC. 2014.** *Lactobacillus rhamnosus* GG protects against non-alcoholic fatty liver disease in mice. *PLOS ONE* 9(1):e80169 DOI 10.1371/journal.pone.0080169.
- Salminen S, Von Wright A, Morelli L, Marteau P, Brassart D, De Vos WM, Fondén R, Saxelin M, Collins K, Mogensen G. 1998.** Demonstration of safety of probiotics—a review. *International Journal of Food Microbiology* 44(1–2):93–106 DOI 10.1016/s0168-1605(98)00128-7.
- Schroeder BO, Birchenough GMH, Stahlman M, Arike L, Johansson MEV, Hansson GC, Bäckhed F. 2018.** Bifidobacteria or fiber protects against diet-induced Microbiota-Mediated Colonic Mucus Deterioration. *Cell Host & Microbe* 23(1):27–40e7  
DOI 10.1016/j.chom.2017.11.004.
- Schwartz MW, Seeley TJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, Leibel RL. 2017.** Obesity pathogenesis: an Endocrine Society scientific statement. *Endocrine Reviews* 38(4):267–296 DOI 10.1210/er.2017-00111.
- Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. 2013.** Effect of a Probiotic and Metformin on Liver Aminotransferases in non-alcoholic Steatohepatitis: a double blind randomized clinical trial. *International Journal of Preventive Medicine* 4(5):531–537.
- Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. 2010.** Saturated fat, carbohydrate, and cardiovascular disease. *American Journal of Clinical Nutrition* 91(3):502–509  
DOI 10.3945/ajcn.2008.26285.
- Speakman J, Hambly C, Mitchell S, Krol E. 2007.** Animal models of obesity. *Obesity Reviews* 8(s1):55–61 DOI 10.1111/j.1467-789X.2007.00319.x.
- Steer TH, Carpenter H, Tuohy K, Gibson GR. 2000.** Perspectives on the role of the human gut microbiota and its modulation by pro- and prebiotics. *Nutrition Research Reviews* 13(2):229–254 DOI 10.1079/095442200108729089.
- Tanentsapf I, Heitmann BL, Adegboye ARA. 2011.** Systematic review of clinical trials on dietary interventions to prevent excessive weight gain during pregnancy among normal weight, overweight and obese women. *BMC Pregnancy and Childbirth* 11(1):81  
DOI 10.1186/1471-2393-11-81.
- Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. 2008.** Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell Host & Microbe* 3(4):213–223  
DOI 10.1016/j.chom.2008.02.015.
- Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006.** An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 444(7122):1027–1031 DOI 10.1038/nature05414.
- Vemuri R, Gundamaraju R, Eri R. 2017.** Role of lactic acid probiotic bacteria in IBD. *Current Pharmaceutical Design* 23(16):2352–2355 DOI 10.2174/1381612823666170207100025.
- Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, Van-Hylckama Vlieg JE, Strissel K, Zhao L, Obin M, Shen J. 2015.** Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. *ISME Journal* 9(1):1–15  
DOI 10.1038/ismej.2014.99.

**WGO. 2017.** World Gastroenterology Organisation Global Guidelines—Probiotics and prebiotics. Available at <http://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf>.

**Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM. 2009.** Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. *Journal of Gastrointestinal Surgery* **13**(7):1198–1204 DOI [10.1007/s11605-009-0891-x](https://doi.org/10.1007/s11605-009-0891-x).

**Yanovski SZ, Yanovski JA. 2014.** Long-term drug treatment for obesity: a systematic and clinical review. *JAMA* **311**(1):74–86 DOI [10.1001/jama.2013.281361](https://doi.org/10.1001/jama.2013.281361).